Malignant Mesothelioma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Malignant Mesothelioma – Pipeline Review, H1 2017’, provides an overview of the Malignant Mesothelioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malignant Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma

– The report reviews pipeline therapeutics for Malignant Mesothelioma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Malignant Mesothelioma therapeutics and enlists all their major and minor projects

– The report assesses Malignant Mesothelioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Malignant Mesothelioma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aduro BioTech Inc

Advantagene Inc

Amphera BV

AnGes MG Inc

arGEN-X BV

ArQule Inc

AVEO Pharmaceuticals Inc

Bayer AG

Biogen Inc

Bionomics Ltd

Biotecnol Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CanBas Co Ltd

CBT Pharmaceuticals Inc

Concordia International Corp

Eagle Pharmaceuticals Inc

Eisai Co Ltd

Eli Lilly and Company

EnGeneIC Ltd

EpiZyme Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Genelux Corp

GlaxoSmithKline Plc

Horizon Pharma Plc

Inventiva

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

MacroGenics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

MolMed SpA

Morphotek Inc

Novartis AG

Ono Pharmaceutical Co Ltd

OSE Immunotherapeutics

Oxford BioMedica Plc

Pharma Mar SA

Philogen SpA

Polaris Pharmaceuticals Inc

Progenra Inc

Seattle Genetics Inc

Sellas Inc

Targovax ASA

TRACON Pharmaceuticals Inc

TREAT U SA

UbiVac LLC

VasGene Therapeutics Inc

Verastem Inc

Virttu Biologics Ltd

Vyriad Inc

Y's Therapeutics Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 10

Global Markets Direct Report Coverage 10

Malignant Mesothelioma Overview 11

Malignant Mesothelioma Therapeutics Development 12

Pipeline Overview 12

Pipeline by Companies 13

Pipeline by Universities/Institutes 18

Products under Development by Companies 19

Products under Development by Universities/Institutes 24

Malignant Mesothelioma Therapeutics Assessment 25

Assessment by Target 25

Assessment by Mechanism of Action 30

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Malignant Mesothelioma Companies Involved in Therapeutics Development 39

Aduro BioTech Inc 39

Advantagene Inc 39

Amphera BV 40

AnGes MG Inc 40

arGEN-X BV 41

ArQule Inc 41

AVEO Pharmaceuticals Inc 42

Bayer AG 42

Biogen Inc 43

Bionomics Ltd 43

Biotecnol Ltd 44

Boehringer Ingelheim GmbH 44

Boston Biomedical Inc 45

Bristol-Myers Squibb Company 45

Calithera Biosciences Inc 46

CanBas Co Ltd 46

CBT Pharmaceuticals Inc 47

Concordia International Corp 47

Eagle Pharmaceuticals Inc 48

Eisai Co Ltd 48

Eli Lilly and Company 49

EnGeneIC Ltd 49

EpiZyme Inc 50

F. Hoffmann-La Roche Ltd 50

Five Prime Therapeutics Inc 51

Genelux Corp 51

GlaxoSmithKline Plc 52

Horizon Pharma Plc 52

Inventiva 53

Juno Therapeutics Inc 53

Karyopharm Therapeutics Inc 54

MacroGenics Inc 54

MedImmune LLC 55

Merck & Co Inc 55

Merck KGaA 56

Millennium Pharmaceuticals Inc 56

MolMed SpA 57

Morphotek Inc 57

Novartis AG 58

Ono Pharmaceutical Co Ltd 59

OSE Immunotherapeutics 59

Oxford BioMedica Plc 60

Pharma Mar SA 60

Philogen SpA 61

Polaris Pharmaceuticals Inc 61

Progenra Inc 62

Seattle Genetics Inc 62

Sellas Inc 63

Targovax ASA 63

TRACON Pharmaceuticals Inc 64

TREAT U SA 64

UbiVac LLC 65

VasGene Therapeutics Inc 65

Verastem Inc 66

Virttu Biologics Ltd 66

Vyriad Inc 67

Y's Therapeutics Co Ltd 67

Malignant Mesothelioma Drug Profiles 68

(epirubicin + staurosporine) Drug Profile 68

alisertib Drug Profile 69

amatuximab Drug Profile 75

anetumab ravtansine Drug Profile 78

ARGX-110 Drug Profile 81

atezolizumab Drug Profile 86

AV-203 Drug Profile 103

avelumab Drug Profile 106

bevacizumab Drug Profile 115

BG-00001 Drug Profile 127

birabresib Drug Profile 128

BMS-986148 Drug Profile 131

BNC-105 Drug Profile 132

brentuximab vedotin Drug Profile 138

CB-839 Drug Profile 165

CBP-501 Drug Profile 174

CBT-501 Drug Profile 177

Cellular Immunotherapy for Oncology Drug Profile 178

Cellular Immunotherapy to Target Mesothelin for Malignant Pleural Mesothelioma and Advanced Leukemia Drug Profile 179

Cellular Immunotherapy to Target Mesothelin for Oncology Drug Profile 180

Cellular Immunotherapy to Target WT1 for Oncology Drug Profile 181

cisplatin Drug Profile 182

CRS-207 Drug Profile 183

CSG-MESO Drug Profile 190

defactinib hydrochloride Drug Profile 191

DFP-10825 Drug Profile 199

doxorubicin hydrochloride Drug Profile 200

DPV-001 Drug Profile 201

durvalumab Drug Profile 203

durvalumab + tremelimumab Drug Profile 217

E-7449 Drug Profile 223

emactuzumab Drug Profile 224

enoblituzumab Drug Profile 225

ESK-1 Drug Profile 228

FL-118 Drug Profile 229

FP-1039 Drug Profile 232

galinpepimut-S Drug Profile 236

ganetespib Drug Profile 240

GEN-0101 Drug Profile 254

Gene Therapy for Glioblastoma and Mesothelioma Drug Profile 256

Gene Therapy for Malignant Pleural Effusion and Solid Tumors Drug Profile 257

Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma Drug Profile 258

GLONC-1 Drug Profile 259

GSK-2256098 Drug Profile 263

GSK-3359609 Drug Profile 265

HSV-1716 Drug Profile 266

HXR-9 Drug Profile 270

iCasp9M28z Drug Profile 271

interferon gamma-1b Drug Profile 272

ipilimumab + nivolumab Drug Profile 277

JTCR-016 Drug Profile 281

KPT-251 Drug Profile 283

KPT-276 Drug Profile 284

LEU-001 Drug Profile 285

lurbinectedin Drug Profile 286

LY-3023414 Drug Profile 294

MesoCancerVac Drug Profile 296

MesoCART Drug Profile 297

MGD-009 Drug Profile 298

Monoclonal Antibody Conjugate to Target Mesothelin for Malignant Mesothelioma Drug Profile 300

Monoclonal Antibody Conjugate to Target Mesothelin for Oncology Drug Profile 301

MTG-201 Drug Profile 303

MTG-202 Drug Profile 305

napabucasin Drug Profile 306

NGR-hTNF Drug Profile 314

nintedanib Drug Profile 320

nivolumab Drug Profile 331

Oncolytic Virus for Malignant Pleural Mesothelioma Drug Profile 372

Oncolytic Virus to Target CD46 and SLC5A5 for Malignant Pleural Mesothelioma Drug Profile 373

ONCOS-102 Drug Profile 374

OSE-2101 Drug Profile 377

Oshadi D + Oshadi R Drug Profile 380

OXB-301 Drug Profile 381

P-0005091 Drug Profile 385

pegargiminase Drug Profile 386

pembrolizumab Drug Profile 395

pemetrexed disodium Drug Profile 443

porfimer sodium Drug Profile 444

rAd-IFN Drug Profile 446

RG-7787 Drug Profile 449

S-588210 Drug Profile 451

Small Molecule for Malignant Mesothelioma and Asbestosis Drug Profile 452

Small Molecule for Oncology Drug Profile 453

Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer Drug Profile 454

TargomiRs Drug Profile 455

tazemetostat Drug Profile 457

TB-535 Drug Profile 466

Teleukin Drug Profile 467

tivantinib Drug Profile 469

trabectedin Drug Profile 475

TRC-102 Drug Profile 482

Vaccine to target Mesothelin for Mesothelioma and Ovarian Cancer Drug Profile 484

Vaccine to Target WT1 for Oncology Drug Profile 485

Vas-01 Drug Profile 486

YS-110 Drug Profile 488

Malignant Mesothelioma Dormant Projects 490

Malignant Mesothelioma Discontinued Products 492

Malignant Mesothelioma Product Development Milestones 493

Featured News & Press Releases 493

Appendix 504

Methodology 504

Coverage 504

Secondary Research 504

Primary Research 504

Expert Panel Validation 504

Contact Us 504

Disclaimer 505

List of Tables

List of Tables

Number of Products under Development for Malignant Mesothelioma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Malignant Mesothelioma Pipeline by Aduro BioTech Inc, H1 2017

Malignant Mesothelioma Pipeline by Advantagene Inc, H1 2017

Malignant Mesothelioma Pipeline by Amphera BV, H1 2017

Malignant Mesothelioma Pipeline by AnGes MG Inc, H1 2017

Malignant Mesothelioma Pipeline by arGEN-X BV, H1 2017

Malignant Mesothelioma Pipeline by ArQule Inc, H1 2017

Malignant Mesothelioma Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Malignant Mesothelioma Pipeline by Bayer AG, H1 2017

Malignant Mesothelioma Pipeline by Biogen Inc, H1 2017

Malignant Mesothelioma Pipeline by Bionomics Ltd, H1 2017

Malignant Mesothelioma Pipeline by Biotecnol Ltd, H1 2017

Malignant Mesothelioma Pipeline by Boehringer Ingelheim GmbH, H1 2017

Malignant Mesothelioma Pipeline by Boston Biomedical Inc, H1 2017

Malignant Mesothelioma Pipeline by Bristol-Myers Squibb Company, H1 2017

Malignant Mesothelioma Pipeline by Calithera Biosciences Inc, H1 2017

Malignant Mesothelioma Pipeline by CanBas Co Ltd, H1 2017

Malignant Mesothelioma Pipeline by CBT Pharmaceuticals Inc, H1 2017

Malignant Mesothelioma Pipeline by Concordia International Corp, H1 2017

Malignant Mesothelioma Pipeline by Eagle Pharmaceuticals Inc, H1 2017

Malignant Mesothelioma Pipeline by Eisai Co Ltd, H1 2017

Malignant Mesothelioma Pipeline by Eli Lilly and Company, H1 2017

Malignant Mesothelioma Pipeline by EnGeneIC Ltd, H1 2017

Malignant Mesothelioma Pipeline by EpiZyme Inc, H1 2017

Malignant Mesothelioma Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Malignant Mesothelioma Pipeline by Five Prime Therapeutics Inc, H1 2017

Malignant Mesothelioma Pipeline by Genelux Corp, H1 2017

Malignant Mesothelioma Pipeline by GlaxoSmithKline Plc, H1 2017

Malignant Mesothelioma Pipeline by Horizon Pharma Plc, H1 2017

Malignant Mesothelioma Pipeline by Inventiva, H1 2017

Malignant Mesothelioma Pipeline by Juno Therapeutics Inc, H1 2017

Malignant Mesothelioma Pipeline by Karyopharm Therapeutics Inc, H1 2017

Malignant Mesothelioma Pipeline by MacroGenics Inc, H1 2017

Malignant Mesothelioma Pipeline by MedImmune LLC, H1 2017

Malignant Mesothelioma Pipeline by Merck & Co Inc, H1 2017

Malignant Mesothelioma Pipeline by Merck KGaA, H1 2017

Malignant Mesothelioma Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Malignant Mesothelioma Pipeline by MolMed SpA, H1 2017

Malignant Mesothelioma Pipeline by Morphotek Inc, H1 2017

Malignant Mesothelioma Pipeline by Novartis AG, H1 2017

Malignant Mesothelioma Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Malignant Mesothelioma Pipeline by OSE Immunotherapeutics, H1 2017

Malignant Mesothelioma Pipeline by Oxford BioMedica Plc, H1 2017

Malignant Mesothelioma Pipeline by Pharma Mar SA, H1 2017

Malignant Mesothelioma Pipeline by Philogen SpA, H1 2017

Malignant Mesothelioma Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Malignant Mesothelioma Pipeline by Progenra Inc, H1 2017

Malignant Mesothelioma Pipeline by Seattle Genetics Inc, H1 2017

Malignant Mesothelioma Pipeline by Sellas Inc, H1 2017

Malignant Mesothelioma Pipeline by Targovax ASA, H1 2017

Malignant Mesothelioma Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Malignant Mesothelioma Pipeline by TREAT U SA, H1 2017

Malignant Mesothelioma Pipeline by UbiVac LLC, H1 2017

Malignant Mesothelioma Pipeline by VasGene Therapeutics Inc, H1 2017

Malignant Mesothelioma Pipeline by Verastem Inc, H1 2017

Malignant Mesothelioma Pipeline by Virttu Biologics Ltd, H1 2017

Malignant Mesothelioma Pipeline by Vyriad Inc, H1 2017

Malignant Mesothelioma Pipeline by Y's Therapeutics Co Ltd, H1 2017

Malignant Mesothelioma Dormant Projects, H1 2017

Malignant Mesothelioma Dormant Projects, H1 2017 (Contd..1), H1 2017

Malignant Mesothelioma Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Malignant Mesothelioma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports